Cell Therapies Pty Ltd. (“Cell Therapies”) and Teijin Limited announced  that they have signed a Memorandum of Understanding (MoU) to strengthen regional infrastructure for cell and gene therapies (CGT), leveraging advanced GMP capabilities and cross-border collaboration to accelerate development and improve patient access across Japan and the wider Asia Pacific region.

This partnership will combine Cell Therapies’ long-standing expertise as Australia’s leading CGT CDMO with Teijin’s strong manufacturing capabilities in CGT and regenerative medicine via their group companies Teijin Regenet Co., Ltd and Japan Tissue Engineering Co., Ltd.（J-TEC）in Japan. The collaboration aims to streamline access to regional markets by enabling cross-border clinical trial and commercial supply, knowledge exchange, and regulatory alignment to support innovative CGT programs.

Through this collaboration, the companies intend to:

• Expand regional GMP manufacturing capacity for cell and gene therapies (CGT)
• Enable efficient technology transfer and multi-site delivery across APAC
• Facilitate clinical trial and market access for advanced therapies in Japan and Australia
• Build long-term infrastructure and capability through joint training and workforce development initiatives

CELL THERAPIES: Bev Menner, Cell Therapies CEO

“This collaboration with Teijin represents an exciting step toward building a truly connected CGT manufacturing network across the Asia Pacific region,” said Bev Menner, CEO of Cell Therapies. “Japan is a critical hub for innovation and patient access, and by combining Teijin’s expertise with our capabilities, we can deliver streamlined, reliable pathways for clinical trials and commercial supply. Our shared goal is to expand access and accelerate delivery of life-changing therapies to patients across the region.”

Teijin: Takayuki Nakano, Ph.D., Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited

“We are delighted to partner with Cell Therapies to enhance access to next-generation therapies for patients in Japan and beyond,” said Takayuki Nakano of Teijin Limited. “This MoU underscores our commitment to strengthening advanced manufacturing capabilities, fostering regulatory harmonization, and building a robust supply chain for cell and gene therapies. By working together, we can drive innovation and contribute to improved patient outcomes throughout the region.”